~~<i id='0828661C58'><strike id='0828661C58'><tt id='0828661C58'><pre id='0828661C58'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

entertainment

leisure time

author：Wikipedia 2025-09-06 05:03:33 - browse：852

The Food and Drug Administration on Thursday approved a gene therapy to treat people with hemophilia A, an inherited and rare bleeding disorder.

The treatment, called Roctavian, is made by BioMarin Pharmaceutical. It was first approved in Europe in August 2022.

Roctavian is a one-time therapy that, in clinical trials, dramatically reduced bleeding episodes and helped patients live without the blood transfusions used to treat the disease. The FDA first rejected Roctavian in 2020, asking BioMarin to amass more data on its safety and long-term durability, and then delayed its decision again to account for additional evidence.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Hospitals owned by private equity see complications spike 25%

knowledge

focus

hotspot

focus

hotspot

Sincetheearlydaysofthepandemic,longCovidhashauntedus:Evenamildacuteinfectionmightleaveyouwithlife-al

WSS

HHS leader on health, climate change and biopharma emissions

The EU Joint Clinical Assessment needs to live up to its promise

CRISPR gene editing developments we’re watching in 2024

STAT Summit: Michael J. Fox on progress in Parkinson's research

Violet CEO on training clinicians to promote more inclusive care

Readout Newsletter: The latest on Moderna, Apellis, and Merck

entertainment

leisure time

knowledge

Supreme Court strikes down use of affirmative action

How to keep neuroscience’s past racism from being its future

Tori Bowie and the unacceptable rates of Black maternal death

CEOs share strategies for surviving biotech slump

DIEP, the 'gold standard' of breast reconstruction, is under threat

Advocates call out 'SNL' over stereotypes, errors in sickle cell skit

Hollywood unions extend contract negotiations for actors

FDA gives detailed accounting of AI

Alkermes shareholders re

FDA gives detailed accounting of AI

focus

Medicare drug price negotiation hasn't dried up venture capital

HHS leader on health, climate change and biopharma emissions

Beam Therapeutics to lay off 20% of its staff, re

Humana’s Medicare Advantage lawsuit should be tossed, DOJ says

Lawmakers consider Medicare pay reforms for doctors

Can sheer will power keep patients alive in their dying hours?

focus

hotspot

focus

hotspot